Finanzas de AbCellera Biologics Inc. (ABCL)ABCLAbCellera Biologics Inc.

AbCellera Biologics Inc. (ABCL) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Research fees, accounting for 98.5% of total sales, equivalent to $8.82M. Another important revenue stream is Licensing revenue. Understanding this composition is critical for investors evaluating how ABCL navigates market cycles within the Biotechnology & Medical Research industry.

Evaluating the bottom line, AbCellera Biologics Inc. maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -1399.43%, while the net margin is -1368.57%. These profitability ratios, combined with a Return on Equity (ROE) of -17.30%, provide a clear picture of how effectively ABCL converts its operational activities into shareholder value.

In the context of the broader market, ABCL competes directly with industry leaders such as ADPT and TNGX. With a market capitalization of $3.82B, it holds a significant position in the sector. When comparing efficiency, ABCL's gross margin of 100.00% stands against ADPT's 71.23% and TNGX's N/A. Such benchmarking helps identify whether AbCellera Biologics Inc. is trading at a premium or discount relative to its financial performance.

Abcellera's financial performance shows a gross margin of 100% across recent quarters, indicating strong revenue generation capability. However, it has been operating at a loss, with a net income loss of $43.2 million in Q1 2026 and a forward P/E of 27.55, reflecting high valuation concerns despite growth potential.